Invalidity dossier
US 10633450
Methods for enhancing anti-tumor antibody therapy
Current assignee: Leland Stanford Junior University
Added 9/20/2026, 5:19:54 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US10633450B2
Title: Methods for enhancing anti-tumor antibody therapy
Patent number: US10633450B2
Application number: US15/669,418
Filed: 2017-08-04
Granted / published: 2020-04-28 (application publication US20180208670A1 on 2018-07-26)
Priority date (as listed): 2009-12-07
Inventors: Holbrook Kohrt; Roch Houot; Ronald Levy; Arash Ash Alizadeh; Matthew J. Goldstein; James Torchia
Assignee: Leland Stanford Junior University (original and current, per the listing)
Legal status (as listed): Expired – Fee Related; adjusted expiration 2031-07-24
Purpose
The title describes methods for enhancing anti-tumor antibody therapy. The prior-art keywords listed are "cells," "tumor," "antibody," "cell," and "day," and the classifications place the subject matter in anti-tumor antibody preparations (A61K39/39558), antineoplastic agents (A61P35/00), and immunoglobulins directed against tumor cells and against growth-factor receptors and CD antigens (C07K16/30, C07K16/2863, C07K16/2878, C07K16/2887, C07K16/2893, C07K16/2896), with tumor-type subclasses for breast, lung, and stomach/intestines. This indicates the claimed subject matter concerns antibody-based cancer therapy rather than a small-molecule drug.
Plain-language scope
Based only on the supplied text, the patent concerns ways to improve the effectiveness of antibody treatments against tumors, involving tumor cells, antibodies, and time-based ("day") treatment parameters. The excerpt does not include any claim language, so the actual scope of the granted claims cannot be stated.
What the excerpt does not establish
This excerpt contains no claims, no written description, no examples, and no figures. It therefore does not establish the specific antibodies, targets, dosing regimens, or combination therapies covered; whether claims are method, composition, or use claims; or any measured results. It also does not establish inventorship disputes, ownership changes, litigation, validity, or prior-art effect. The legal-status and priority statements are expressly flagged as assumptions, not legal conclusions.
Source: https://patents.google.com/patent/[US10633450](/patent/US10633450)/en
Generated 10/1/2026, 10:02:48 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10633450. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.